NCT01515189已完成3 期
A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma
Bristol-Myers Squibb101 个研究点 分布在 11 个国家目标入组 831 人开始时间: 2012年2月17日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 831
- 试验地点
- 101
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable Stage III or Stage IV melanoma
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
排除标准
- •Brain metastases with symptoms or requiring treatment
- •History of autoimmune disease
结局指标
主要结局
Overall Survival (OS)
时间窗: Approximately 48 months (assessed up to February 2016)
OS is defined for each participant as the time between randomization date and death due to any cause. The survival time for participants who had not died was censored at the last known alive date. Median and associated 2-sided 95% confidence intervals were calculated using the method of Brookmeyer and Crowley.
次要结局
- Progression Free Survival (PFS) by mWHO Criteria(From date of randomization until 540 death events occurred (approximately 48 months))
- Duration of Response (DOR) by mWHO Criteria(From date of randomization until 540 death events occurred (approximately 48 months))
- Duration of Stable Disease by mWHO Criteria(From date of randomization until 540 death events occurred (approximately 48 months))
- Best Overall Response Rate (BORR) by mWHO Criteria(From date of randomization until 540 death events occurred (approximately 48 months))
- Disease Control Rate (DCR) by mWHO Criteria(From date of randomization until 540 death events occurred (approximately 48 months))
- Rate of Overall Survival(Approximately 66 months)
- Overall Survival of Participants With Brain Metastases at Baseline(From date of randomization until 540 death events occurred (approximately 48 months))
研究者
研究点 (101)
Loading locations...
相似试验
进行中（未招募）
3 期
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryMelanoma of Unknown PrimaryRecurrent MelanomaStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7NCT01274338National Cancer Institute (NCI)1,673
终止
2 期
Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaMelanomaNCT01709162Bristol-Myers Squibb31
已完成
1 期
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, DacarbazineAdvanced MelanomaNCT00796991Bristol-Myers Squibb72
已完成
2 期
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryRecurrent MelanomaStage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7NCT01708941National Cancer Institute (NCI)88
已完成
2 期
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyMelanomaNCT02731729Parker Institute for Cancer Immunotherapy20